As of 2024-12-14, the EV/EBITDA ratio of Vir Biotechnology Inc (VIR) is -1.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VIR's latest enterprise value is 857.66 mil USD. VIR's TTM EBITDA according to its financial statements is -557.30 mil USD. Dividing these 2 quantities gives us the above VIR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 15.9x | 15.6x |
| Forward P/E multiples | 15.3x - 17.2x | 15.5x |
| Fair Price | (60.69) - (63.12) | (61.70) |
| Upside | -914.6% - -947.2% | -928.2% |
| Date | EV/EBITDA |
| 2024-11-29 | -1.66 |
| 2024-11-27 | -1.64 |
| 2024-11-26 | -1.58 |
| 2024-11-25 | -1.54 |
| 2024-11-22 | -1.46 |
| 2024-11-21 | -1.42 |
| 2024-11-20 | -1.36 |
| 2024-11-19 | -1.41 |
| 2024-11-18 | -1.44 |
| 2024-11-15 | -1.68 |
| 2024-11-14 | -1.83 |
| 2024-11-13 | -1.92 |
| 2024-11-12 | -1.98 |
| 2024-11-11 | -2.14 |
| 2024-11-08 | -2.07 |
| 2024-11-07 | -2.11 |
| 2024-11-06 | -2.21 |
| 2024-11-05 | -2.08 |
| 2024-11-04 | -2.01 |
| 2024-11-01 | -1.99 |
| 2024-10-31 | -1.55 |
| 2024-10-30 | -1.58 |
| 2024-10-29 | -1.58 |
| 2024-10-28 | -1.61 |
| 2024-10-25 | -1.55 |
| 2024-10-24 | -1.51 |
| 2024-10-23 | -1.56 |
| 2024-10-22 | -1.58 |
| 2024-10-21 | -1.59 |
| 2024-10-18 | -1.58 |
| 2024-10-17 | -1.61 |
| 2024-10-16 | -1.64 |
| 2024-10-15 | -1.61 |
| 2024-10-14 | -1.59 |
| 2024-10-11 | -1.57 |
| 2024-10-10 | -1.51 |
| 2024-10-09 | -1.51 |
| 2024-10-08 | -1.51 |
| 2024-10-07 | -1.53 |
| 2024-10-04 | -1.61 |
| 2024-10-03 | -1.51 |
| 2024-10-02 | -1.60 |
| 2024-10-01 | -1.57 |
| 2024-09-30 | -1.55 |
| 2024-09-27 | -1.56 |
| 2024-09-26 | -1.50 |
| 2024-09-25 | -1.49 |
| 2024-09-24 | -1.56 |
| 2024-09-23 | -1.58 |
| 2024-09-20 | -1.62 |